The Food and Drug Administration approved Ctexli for the treatment of cerebrotendinous xanthomatosis in adults. “Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease,” the agency stated. The approval of Ctexli was granted to Mirum Pharmaceuticals (MIRM).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM: